AZD1152 in Patients With Advanced Solid Malignancies-Study 1

Inclusion Criteria: * Histological or cytological confirmation of a solid, malignant tumour * At least measurable or non measurable site of disease as defined by modified RECIST criteria. Exclusion Criteria: * Participation in an investigational drug study within 30 days prior to entry or who have not recovered from the effects of an investigational study drug * Treatment with radiotherapy/chemotherapy with 4 weeks of first dose * Recent major surgery within 4 weeks prior to entry to the study